Search

Displaying results 2721 - 2730 of 4004 in total
  1. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages

  2. Drug

    Nefazodone

    go.drugbank.com/drugs/DB01149
    ApprovedWithdrawn

    On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States.

  3. Drug

    Lifastuzumab vedotin

    go.drugbank.com/drugs/DB15400
    Investigational

    Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum

  4. Drug

    SBT101

    go.drugbank.com/drugs/DB18139
    Investigational

    SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1

  5. Drug

    Bopindolol

    go.drugbank.com/drugs/DB08807
    Experimental

    Bopindolol (INN) is an ester prodrug for the beta blocker pindolol.

    Categories: Beta Blocking Agents, Non-Selective
  6. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.

    Categories: Agents Acting on the Renin-Angiotensin System
  7. Drug

    Inodiftagene vixteplasmid

    go.drugbank.com/drugs/DB16017
    Investigational

    Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed non-protein

  8. Drug

    SIG-207

    go.drugbank.com/drugs/DB18547
    Experimental

    SIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified

  9. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

  10. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.